


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army 126

In Re Application Of: Meyerhoff, et al.



Serial No.
09/692,938

Filing Date
October 20, 2000

Examiner
Gupta

Group Art Unit
1653

Title: **Pharmaceutical Composition Containing PGLU-GLU-Pro and Method For Treating Diseases and Injuries to the Brain, Spinal Cord and Retina Using Same**

#13
5/8/03
3/12/03

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

Army 126

In Re Application: Meyerhoff, et al.

FEB 27 2003

Serial No.

09/692,938

Filing Date

October 20, 2000

Examiner

Gupta

Group Art Unit

1614

Pharmaceutical Composition Containing PGLU-GLU-Pro and Method For Treating Diseases and
to the Brain, Spinal Cord and Retina Using Same

RECEIVED

MAR 04 2003

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37

TECH CENTER 1600/2900

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited February 21, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.




Signature of Person Mailing Correspondence

Caroline Nash

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: February 21, 2003

Caroline Nash, Reg. No. 36,329

Nash & Titus, LLC

3415 Brookeville Road

Brookeville, MD 20833

301 924-9500

for: Elizabeth Arwine, Reg. No. 45,867

U.S. Army Medical Research and Materiel Command

CC:

(Use several sheets if necessary)

Army 1

09/692,938

Meyerhoff, et al.

October 20, 2000

1653

FEB 27 2003

PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

cc	Koenig, et al., In vitro neuroprotection against glutamate-induced toxicity by pGlu-Glu-Pro-NH2 (EEP), Peptides 22 (2001) 2091-2097.
dd	Faden, Effects of TRH on Blood Flow, Circulatory Shock, and CNS Injury, Annals New York Academy of Sciences, page 285-387, (1989)

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

Army 1

Application Number

09/692,938

Applicant(s)

Meyerhoff, et al.

Filing Date

October 20, 2000

Group Art Unit

1653

FEB 27 2003

*EXAMINER
INITIAL

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Marangell, Effects of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in Refractory Depressed Patients, Arch Gen Psychiatry/Vol. 54, Mar 1997.

ee

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.